Skip to main content

Table 1 Baseline demographics and disease characteristics

From: Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study

CharacteristicsRanibizumab 0.5 mg
VA only (Group I)
Ranibizumab 0.5 mg
VA and/or OCT (Group II)
Randomized set
n = 335
12-month completers
n = 151
Randomized set
n = 336
12-month completers n = 154
Mean (SD) age, years73.9 (7.9)74.1 (8.10)75.3 (7.9)74.9 (7.9)
Gender, Female, n (%)213 (63.6)91 (60.3)194 (57.7)93 (60.4)
Race, Caucasian, n (%)320 (95.5)150 (99.3)325 (96.7)154 (100)
Mean (SD) BCVA, ETDRS letters61.9 (12.84)60.9 (13.10)59.8 (12.64)60.2 (12.21)
Mean (SD) CSFT, μm500.9 (203.58)517.7 (201.8)512.7 (193.80)515.3 (198.37)
Mean (SD) time since first diagnosis of nAMD, weeks6.6 (41.74)8.3 (57.40)4.8 (15.65)5.5 (20.87)
Mean (SD) central subfield volume on OCT, mm30.4 (0.16)0.4 (0.16)0.4 (0.15)0.4 (0.16)
Presence of subretinal fluid on OCT, Yes, n (%)257 (76.7)126 (83.4)270 (80.4)132 (85.7)
Presence of fluid beneath the retinal pigment epithelium on OCT, Yes, n (%)122 (36.4)59 (39.1)132 (39.3)59 (38.3)
Presence of cysts on OCT, Yes, n (%)150 (44.8)77 (51.0)174 (51.8)78 (50.6)
Presence of extrafoveal CNV lesions on FA, Yes, n (%)123 (36.7)56 (37.1)108 (32.1)53 (34.4)
Lesion type on FA, n (%)
 - 100% classic73 (21.8)40 (26.5)72 (21.4)35 (22.7)
 - Predominantly classic20 (6.0)7 (4.6)27 (8.0)14 (9.1)
 - Minimally classic36 (10.7)18 (11.9)33 (9.8)16 (10.4)
 - Occult with no classic component123 (36.7)61 (40.4)114 (33.9)55 (35.7)
  1. Randomized set comprises all randomized patients
  2. BCVA best-corrected visual acuity, CSFT central subfield thickness, ETDRS Early Treatment Diabetic Retinopathy Study, FA fluorescein angiography, n number of patients in treatment group with Month 12 VA (for 12-month completers), nAMD neovascular age-related macular degeneration, OCT optical coherence tomography, SD standard deviation, VA visual acuity